🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06596811
Active, not recruiting Observational

Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring

NCT06596811 · tracked via the Priya Life Science China tracker
Sponsor
Qianfoshan Hospital
Phase
Observational
Started
2024-09-01
Last updated
2024-09-19

Condition(s) studied

AKITherapeutic Drug Monitoring (TDM)

Study summary

In this study, the investigators will focus on hospitalized patients using cyclosporine and develop an acute kidney injury risk prediction model through in-depth analysis of electronic medical record data, employing interpretable deep learning methods. This model aims to provide timely decision-making support for clinicians regarding prevention and treatment. Compared to traditional machine learning models, deep neural network models can extract deeper features from complex medical data and perform more precise pattern recognition, thereby improving the accuracy and reliability of predictions. By developing a prediction tool based on interpretable deep learning models, the investigators will be able to better assess the association between the use of CNI-class immunosuppressants and acute kidney injury, explore targeted prevention strategies, and offer more accurate prediction and intervention guidance for clinicians. Additionally, this study has significant socioeconomic benefits and promising prospects for application and promotion.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. During hospitalization, tacrolimus or cyclosporine was used, and therapeutic drug monitoring was conducted according to standard procedures. 2. Aged 18 years or older at the time of admission. 3. Length of hospital stay \> 48 hours. 4. At least 2 serum creatinine tests were conducted during hospitalization. Exclusion Criteria: 1. Chronic kidney disease stage 5 was achieved before admission. 2. Incomplete clinical data. 3. Serum creatinine levels were consistently below 40 mmol/L during hospitalization.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan China

More Qianfoshan Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06596811 on ClinicalTrials.gov ↗ ← All trials in China